BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns Outperform Rating from Royal Bank of Canada

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “outperform” rating restated by Royal Bank of Canada in a research note issued on Tuesday, Benzinga reports. They currently have a $10.00 price target on the biotechnology company’s stock. Royal Bank of Canada’s price target would indicate a potential upside of 39.28% from the stock’s current price.

Several other brokerages also recently commented on BCRX. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Barclays lifted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday. JMP Securities upped their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a report on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $14.67.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded down $0.17 during mid-day trading on Tuesday, hitting $7.18. The company’s stock had a trading volume of 587,512 shares, compared to its average volume of 2,963,189. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -9.84 and a beta of 1.89. The company’s fifty day simple moving average is $7.84 and its 200-day simple moving average is $6.95. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the previous year, the firm posted ($0.19) EPS. The business’s revenue was up 35.1% on a year-over-year basis. On average, sell-side analysts predict that BioCryst Pharmaceuticals will post -0.37 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its position in shares of BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after purchasing an additional 375,890 shares during the period. Rice Hall James & Associates LLC boosted its position in shares of BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of BioCryst Pharmaceuticals by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,791 shares of the biotechnology company’s stock valued at $302,000 after acquiring an additional 15,544 shares during the period. Semanteon Capital Management LP acquired a new position in BioCryst Pharmaceuticals during the 3rd quarter valued at about $1,137,000. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of BioCryst Pharmaceuticals by 44.5% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 17,344 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 5,340 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.